Prophase Labs Share Price (NASDAQ: PRPH)

$0.34

▲

-0.01

(-2.86%)

Last updated on August 30, 2025 at 1:28 am IST

$₹

Check the interactive Prophase Labs Stock chart to analyse performance

Prophase Labs stock performance

as on August 30, 2025 at 1:28 am IST

Today's Low:$0.34
Today's High:$0.34
$0.34
1.12%
Downside
Day's Volatility :2.35%
Upside
1.25%
52 Weeks Low:$0.22
52 Weeks High:$3.00
$0.34
35.91%
Downside
52 Weeks Volatility :92.74%
Upside
88.67%

Prophase Labs Stock Returns

Period	Prophase Labs Inc	Index (Russel 2000)
3 Months	-9.79%	0.0%
6 Months	-19.18%	0.0%
1 Year	-86.68%	0.0%
3 Years	-97.05%	-4.1%

Prophase Labs Inc Key Stats

Check Prophase Labs key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.35
Open	$0.3399
Today's High	$0.3443
Today's Low	$0.3362
Market Capitalization	$14.4M
Today's Volume	$259.8K
52 Week High	$3.0
52 Week Low	$0.2179
Revenue TTM	$5.6M
EBITDA	$-25.5M
Earnings Per Share (EPS)	$-2.07
Profit Margin	0.0%
Quarterly Earnings Growth YOY	-0.95%
Return On Equity TTM	-171.81%

Stock Returns calculator for Prophase Labs Stock including INR - Dollar returns

The Prophase Labs stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Prophase Labs investment value today

Current value as on today

₹18,723

Returns

₹81,277

(-81.28%)

Returns from Prophase Labs Stock

₹86,561 (-86.56%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Prophase Labs Stock

506.67%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Investment in Prophase Labs Shares from India has grown by 506.67% over the past 30 days, indicating increased transactional activity.

461%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Prophase Labs Stock from India on INDmoney has increased by 461% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Prophase Labs Inc

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
0.98%
FourWorld Capital Management LLC
0.91%
Renaissance Technologies Corp
0.72%
HighTower Advisors, LLC
0.55%
Geode Capital Management, LLC
0.55%
Quinn Opportunity Partners LLC
0.53%

Analyst Recommendation on Prophase Labs Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Prophase Labs(by analysts ranked 0 to 5 stars)

Prophase Labs Share Price Target

What analysts predicted

Upside of 3958.82%

Target:

$13.80

Current:

$0.34

Prophase Labs share price target is $13.80, a slight Upside of 3958.82% compared to current price of $0.34 as per analysts' prediction.

Prophase Labs Stock Insights

Price Movement
In the last 1 year, PRPH stock has moved down by -87.5%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.43M → 1.24M (in $), with an average decrease of 12.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 3.96M → -4.47M (in $), with an average decrease of 212.8% per quarter
PRPH vs IDXX (1 yr)
In the last 1 year, Idexx Laboratories, Inc. has given 34.2% return, outperforming this stock by 121.7%
PRPH vs IDXX (3 yr)
In the last 3 years, Idexx Laboratories, Inc. has given 85.8% return, outperforming this stock by 183.0%
Price to Sales
ForPRPH every $1 of sales, investors are willing to pay $1.8, whereas for Idexx Laboratories, Inc., the investors are paying $13.0 for every $1 of sales.

Prophase Labs Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$9.9M	↓ 24.76%
Net Income	$-3.1M	↑ 80.8%
Net Profit Margin	-31.86%	↓ 18.6%

	FY20	Y/Y Change
Revenue	$14.5M	↑ 46.96%
Net Income	$-2.1M	↓ 32.45%
Net Profit Margin	-14.64%	↑ 17.22%

	FY21	Y/Y Change
Revenue	$79.0M	↑ 444.59%
Net Income	$6.3M	↓ 395.2%
Net Profit Margin	7.94%	↑ 22.58%

	FY22	Y/Y Change
Revenue	$122.6M	↑ 55.17%
Net Income	$18.5M	↑ 194.32%
Net Profit Margin	15.05%	↑ 7.11%

	FY23	Y/Y Change
Revenue	$44.4M	↓ 63.81%
Net Income	$-16.8M	↓ 190.9%
Net Profit Margin	-37.81%	↓ 52.86%

	FY24	Y/Y Change
Revenue	$6.8M	↓ 84.75%
Net Income	$-53.4M	↑ 217.98%
Net Profit Margin	-788.24%	↓ 750.43%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$3.6M	↑ 3.86%
Net Income	$-6.3M	↓ 28.41%
Net Profit Margin	-172.4%	↑ 77.7%

	Q2 FY24	Q/Q Change
Revenue	$2.5M	↓ 31.92%
Net Income	$-6.2M	↓ 1.79%
Net Profit Margin	-248.71%	↓ 76.31%

	Q3 FY24	Q/Q Change
Revenue	$3.1M	↑ 27.16%
Net Income	$-6.6M	↑ 7.05%
Net Profit Margin	-209.38%	↑ 39.33%

	Q4 FY24	Q/Q Change
Revenue	$-2.5M	↓ 178.96%
Net Income	$-34.4M	↑ 421.62%
Net Profit Margin	1.4K%	↑ 1592.59%

	Q1 FY25	Q/Q Change
Revenue	$1.4M	↓ 157.61%
Net Income	$4.0M	↓ 111.54%
Net Profit Margin	277.15%	↓ 1106.06%

	Q2 FY25	Q/Q Change
Revenue	$1.2M	↓ 12.86%
Net Income	$-4.5M	↓ 212.76%
Net Profit Margin	-358.62%	↓ 635.77%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$2.6M	↓ 45.3%

	FY20	Y/Y Change
Profit	$4.6M	↑ 76.14%

	FY21	Y/Y Change
Profit	$32.8M	↑ 612.42%

	FY22	Y/Y Change
Profit	$70.7M	↑ 115.32%

	FY23	Y/Y Change
Profit	$16.2M	↓ 77.02%

	FY24	Y/Y Change
Profit	$-150.0K	↓ 100.92%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-433.0K	↓ 85.83%

	Q2 FY24	Q/Q Change
Profit	$-476.0K	↑ 9.93%

	Q3 FY24	Q/Q Change
Profit	$-165.0K	↓ 65.34%

	Q4 FY24	Q/Q Change
Profit	$924.0K	↓ 660.0%

	Q1 FY25	Q/Q Change
Profit	$526.0K	↓ 43.07%

	Q2 FY25	Q/Q Change
Profit	$734.0K	↑ 39.54%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-841.0K	↓ 60.31%
Investing Cash Flow	$5.5M	↓ 53.27%
Financing Cash Flow	$-5.8M	↓ 48.76%

	FY20	Y/Y Change
Operating Cash Flow	$-2.6M	↑ 208.2%
Investing Cash Flow	$-1.0M	↓ 118.33%
Financing Cash Flow	$10.0M	↓ 271.59%

	FY21	Y/Y Change
Operating Cash Flow	$-13.6M	↑ 425.42%
Investing Cash Flow	$-19.7M	↑ 1835.63%
Financing Cash Flow	$35.1M	↑ 251.62%

	FY22	Y/Y Change
Operating Cash Flow	$28.6M	↓ 309.64%
Investing Cash Flow	$-2.1M	↓ 89.44%
Financing Cash Flow	$-26.0M	↓ 174.08%

	FY23	Y/Y Change
Operating Cash Flow	$-11.3M	↓ 139.75%
Investing Cash Flow	$-1.4M	↓ 34.09%
Financing Cash Flow	$5.8M	↓ 122.12%

	FY24	Y/Y Change
Operating Cash Flow	$-17.5M	↑ 54.55%
Investing Cash Flow	$2.4M	↓ 276.92%
Financing Cash Flow	$14.2M	↑ 146.4%

Q1 FY24

Q2 FY24

Q3 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-5.1M	↑ 2303.29%
Investing Cash Flow	$2.4M	↓ 292.64%
Financing Cash Flow	$2.3M	↓ 22.33%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-4.8M	↓ 5.88%
Investing Cash Flow	$124.0K	↓ 94.91%
Financing Cash Flow	$5.3M	↑ 134.39%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-4.0M	↓ 16.36%
Investing Cash Flow	$-97.0K	↓ 178.23%
Financing Cash Flow	$2.9M	↓ 46.35%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-3.4M	↓ 5.32%
Investing Cash Flow	$853.0K	-
Financing Cash Flow	$1.9M	↓ 29.71%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$17.2M	↓ 608.52%
Investing Cash Flow	$67.0K	↓ 92.15%
Financing Cash Flow	$261.0K	↓ 86.53%

Prophase Labs Technicals Summary

Sell

Neutral

Buy

Prophase Labs is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Prophase Labs Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Prophase Labs Inc	3.37%	-19.18%	-86.68%	-97.05%	-87.51%
Agilent Technologies Inc.	10.74%	-0.51%	-9.55%	-2.51%	24.3%
Idexx Laboratories, Inc.	20.6%	47.74%	37.7%	84.56%	62.07%
Thermo Fisher Scientific, Inc.	6.38%	-5.93%	-18.77%	-10.56%	13.57%
Danaher Corp.	4.47%	0.1%	-22.08%	-24.82%	-1.19%
Iqvia Holdings Inc.	4.47%	3.11%	-23.4%	-9.93%	15.42%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Prophase Labs Inc	NA	NA	0.0	-0.56	-1.72	-0.29	NA	0.28
Agilent Technologies Inc.	29.29	29.29	1.84	5.57	0.2	0.08	0.0	22.46
Idexx Laboratories, Inc.	53.78	53.78	4.84	12.6	0.65	0.23	NA	18.2
Thermo Fisher Scientific, Inc.	28.33	28.33	1.99	22.49	0.13	0.05	0.0	133.77
Danaher Corp.	43.68	43.68	2.06	7.77	0.07	0.04	0.01	73.1
Iqvia Holdings Inc.	27.61	27.61	1.08	11.87	0.2	0.05	NA	33.99

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Prophase Labs Inc	Buy	$14.4M	-87.51%	NA	0.0%
Agilent Technologies Inc.	Buy	$35.7B	24.3%	29.29	17.97%
Idexx Laboratories, Inc.	Buy	$51.8B	62.07%	53.78	24.41%
Thermo Fisher Scientific, Inc.	Buy	$184.9B	13.57%	28.33	15.24%
Danaher Corp.	Buy	$147.0B	-1.19%	43.68	14.21%
Iqvia Holdings Inc.	Buy	$32.4B	15.42%	27.61	7.88%

About Prophase Labs Inc

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Organization	Prophase Labs
Employees	96
CEO	Mr. Ted William Karkus
Industry	Consumer Non-Durables

Key Management of Prophase Labs Inc

Name	Title
Mr. Ted William Karkus	Chairman & CEO
Mr. Kamal Obbad	Senior VP and Director of Sales & Marketing - Nebula Genomics
Mr. Jason Karkus	President of Nebula Genomics
Mr. Lance Bisesar	Corporate Controller

Important FAQs about investing in PRPH Stock from India :

What is Prophase Labs share price today?

Prophase Labs share price today is $0.34 as on August 30, 2025 at 1:28 am IST at the close of the market. Prophase Labs share today touched a day high of $0.34 and a low of $0.34.

What is the 52 week high and 52 week low for Prophase Labs share?

Prophase Labs share touched a 52 week high of $3.00 and a 52 week low of $0.22. Prophase Labs stock price today i.e. August 30, 2025 at 1:28 am IST is closed at $0.34, lower by 88.67% versus the 52 week high.

How to invest in Prophase Labs Stock (PRPH) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Prophase Labs on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Prophase Labs Shares that will get you 4.4118 shares as per Prophase Labs share price of $0.34 per share as on August 30, 2025 at 1:28 am IST.

What is the minimum amount required to buy Prophase Labs Stock (PRPH) from India?

Indian investors can start investing in Prophase Labs (PRPH) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Prophase Labs stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Prophase Labs share’s latest price of $0.34 as on August 30, 2025 at 1:28 am IST, you will get 29.4118 shares of Prophase Labs. Learn more about fractional shares .

What are the returns that Prophase Labs has given to Indian investors in the last 5 years?

Prophase Labs stock has given -87.51% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?